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Abstract
Background
A wide range of screening tools are available to detect common mental disorders (CMDs),
but few have been specifically developed for populations in low and middle income coun-
tries (LMIC). Cross-cultural application of a screening tool requires that its validity be
assessed against a gold standard diagnostic interview. Validation studies of brief CMD
screening tools have been conducted in several LMIC, but until now there has been no
review of screening tools for all CMDs across all LMIC populations.
Methods
A systematic review with broad inclusion criteria was conducted, producing a comprehen-
sive summary of brief CMD screening tools validated for use in LMIC populations. For each
validation, the diagnostic odds ratio (DOR) was calculated as an easily comparable mea-
sure of screening tool validity. Average DOR results weighted by sample size were calcu-
lated for each screening tool, enabling us to make broad recommendations about best
performing screening tools.
Results
153 studies fulfilled our inclusion criteria. Because many studies validated two or more
screening tools, this corresponded to 273 separate validations against gold standard diag-
nostic criteria. We found that the validity of every screening tool tested in multiple settings
and populations varied between studies, highlighting the importance of local validation.
Many of the best performing tools were purposely developed for a specific population; how-
ever, as these tools have only been validated in one study, it is not possible to draw broader
conclusions about their applicability in other contexts.
PLOS ONE | DOI:10.1371/journal.pone.0156939 June 16, 2016 1 / 14
a11111
OPEN ACCESS
Citation: Ali G-C, Ryan G, De Silva MJ (2016)
Validated Screening Tools for Common Mental
Disorders in Low and Middle Income Countries: A
Systematic Review. PLoS ONE 11(6): e0156939.
doi:10.1371/journal.pone.0156939
Editor: Jonathan K Burns, University of Kwazulu-
Natal, SOUTH AFRICA
Received: January 14, 2016
Accepted: May 23, 2016
Published: June 16, 2016
Copyright: © 2016 Ali et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Data is available from
Figshare: S1 Results Database https://figshare.com/
s/50ed7c594f44a295a177 10.6084/m9.figshare.
3406615 S2 Included Studies https://figshare.com/s/
8d980965cabe303629d8 10.6084/m9.figshare.
3412693 S3 Quality Appraisal https://figshare.com/s/
b38b30500046ce56445d 10.6084/m9.figshare.
3413614
Funding: Grand Challenges Canada EPPHZG35-10
http://www.grandchallenges.ca/. The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Conclusions
Of the tools that have been validated in multiple settings, the authors broadly recommend
using the SRQ-20 to screen for general CMDs, the GHQ-12 for CMDs in populations with
physical illness, the HADS-D for depressive disorders, the PHQ-9 for depressive disorders
in populations with good literacy levels, the EPDS for perinatal depressive disorders, and
the HADS-A for anxiety disorders. We recommend that, wherever possible, a chosen
screening tool should be validated against a gold standard diagnostic assessment in the
specific context in which it will be employed.
Introduction
The Importance of Common Mental Disorders
TheWorld Health Organisation (WHO) International Classification of Disease (ICD-10) defines
commonmental disorders (CMDs) as ‘mood disorders’ and ‘neurotic, stress-related and somato-
form disorders’ [1]. These include depressive, anxiety and post-traumatic stress disorders
(PTSD). CMDs have been shown to negatively impact a wide range of health, economic and
social outcomes [2, 3]. Co-morbidity with other health problems is high and worsens prognosis
[4–6], and prevalence of CMDs is higher in low-income groups [7], ethnic minorities [8] and
migrant populations [9, 10]. Both researchers and clinicians are therefore increasingly interested
in screening for anxiety, depression and PTSD in the populations they study and treat.
The Importance of Screening Tools
Brief screening tools are essential for improving mental health care in low and middle income
countries (LMIC). The majority of health workers have neither the time nor training to admin-
ister complex diagnostic interviews to all individuals at risk of psychiatric illness. Adopting
appropriate screening instruments is therefore an important first step to integrate care for
CMDs into existing primary health care (PHC) services, particularly those attended by high
risk populations, such as HIV or maternity clinics [11].
Brief CMD screening tools can also be used to enhance research and training in LMIC. The
availability of short, simple tools will encourage researchers to screen for CMDs in their study
populations, facilitating research into the effects of untreated mental illness on priority health,
economic and social issues. Screening tools can also be used as part of a mental health training
package for PHC workers [12]. By providing a succinct overview of symptoms, they teach health
workers what to look for and thus improve their ability to detect mental health problems.
The Importance of Cultural Validation
A wide range of screening tools is available to detect CMDs, but few have been specifically
developed for LMIC populations. There is concern that using tools developed for high-income
country populations will miss cases in LMIC. In sub-Saharan Africa, for example, distress is
believed to be more commonly expressed through somatic symptoms and local idioms [13].
Although CMDs are prevalent in all regions worldwide, clinical presentation does differ
between settings [14]. For example, previous validations of the Edinburgh postnatal depression
scale (EPDS) in LMIC have generally found lower optimum cut-off scores than those recom-
mended for the populations in which the tools were developed [15]. This may be due to cross-
cultural differences in somatization of symptoms and expression of emotional distress, leading
to under-recognition or misidentification of psychiatric morbidity [13].
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Screening tool validity is the extent to which an instrument measures what it claims to mea-
sure. For cross-cultural application of a screening tool, it is most important to assess criterion
validity [16]. This involves comparing the results of a screening tool to those of a recognised
gold standard, defined as ‘a relatively irrefutable standard that constitutes recognized and
accepted evidence that a certain disease exists’ [17]. The most reliable gold standards employed
in cross-cultural mental health research are diagnostic interviews conducted by qualified men-
tal health professionals [16].
The Importance of this Systematic Review
Validation studies of brief CMD screening tools have been conducted in several LMIC, but sig-
nificant gaps remain. Until now there has been no pooled resource from which researchers or
implementers can identify the best-performing tools for their needs. Several smaller reviews
have been conducted of screening tool validation studies for particular disorders in particular
settings or populations–such as perinatal depression in Africa [18], depression in Spanish-
speaking populations [19], and depression in Chinese older adults [20]–but to date there has
been no review of screening tools for all CMDs across all LMIC populations. The project pre-
sented here updates and builds upon a 2012 systematic review of depression (as opposed to all
CMD) screening tools validated in LMIC [21], which identified 19 studies.
By conducting a comprehensive systematic review of studies validating brief CMD screen-
ing tools for use in LMIC, we provide researchers, policy makers and health care providers
with a comprehensive, evidence-based summary of the most appropriate CMD screening tools
for use in particular settings and populations. We aim to provide a ‘one-stop shop’ at which
researchers can compare the performance of screening tools in settings and populations similar
to those in which they work, and identify appropriate cut-off points for probable diagnosis of
the disorders of interest. A copy of the results database is available as a web appendix (S1 File),
on figshare and on the Mental Health Innovation Network (MHIN), presenting the results of
all validation studies identified by this review.
Study Aim
We aimed to conduct a high quality systematic review of studies validating brief CMD screen-
ing tools for use in LMIC populations, using criterion validity as the outcome measure and
gold standard diagnostic assessment as the comparison.
Methods
We did not publish a study protocol in advance of conducting this review, but no methodologi-
cal changes were made between study conception and completion.
Search Strategy
The search terms listed in Fig 1 were used to identify relevant papers from the EMBASE, Global
Health, MEDLINE, PsychExtra and PsychInfo databases. The search was run on 11th Decem-
ber 2013 and results were not restricted by publication date or language.
Study Selection
All abstracts returned by the database search were reviewed for possible inclusion. Full texts
were retrieved for those identified as potentially relevant, and these were assessed for inclusion
using the criteria below. The reference lists of all studies that met these criteria were then used
to identify additional studies for inclusion, as were all systematic reviews identified by the
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initial search. To reduce bias caused by human error, the second author repeated 10% of the
study selection process at every stage. Rates of agreement were consistently high between the
two reviewers, with any discrepancies resolved through discussion.
Inclusion Criteria
Study design. Papers were eligible for inclusion in this review if they reported a criterion
validation study of one or more screening tools.
Disorders. We included screening tool validation studies for any CMD included in the
World Health Organisation’s International Classification of Diseases, version 10 [1].
Low and Middle Income Countries. Studies were included if conducted in a LMIC, as
defined by the World Bank’s country classification [22].
Gold standard. To be eligible for inclusion, the study must have compared the screening
tool’s performance with that of a recognised gold standard. The preferred gold standard was
diagnostic assessment by a mental health professional. Where the gold standard diagnosis was
made by a lay interviewer or general medical professional, the study was deemed acceptable
only if a well-structured diagnostic interview suitable for delivery by a non-mental health pro-
fessional was employed.
Exclusion Criteria
In order to maximise the breadth of the review, all studies which met the above inclusion crite-
ria were included irrespective of their methodological quality (see below). All study settings
and population groups were included and details of each study are fully reported in the data
extraction tables. This approach was designed to maximise the utility of the study findings. It
enables researchers and health care providers to consider the full range of circumstances for
which tools have been validated, and to identify which tools perform best in the settings and
populations that best reflect their own research or clinical context.
Quality Appraisal
Study quality was assessed against a modified version of Greenhalgh’s ten-item checklist for
papers reporting validations of diagnostic or screening tests [23]. The final quality criteria
employed for this review are presented in Table 1 below.
Studies that met all the quality criteria were considered to be of ‘very good’ quality. Those
that met criteria 1, 2 and 3 and at least one of criteria 4, 5 and 6 were classed as ‘good’ quality.
Studies were classified as ‘fair’ quality if they failed to avoid work-up bias, or if they avoided
Fig 1. Database search strategy.
doi:10.1371/journal.pone.0156939.g001
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work-up bias but did not meet any of criteria 4 to 6. Those that did not perform receiver opera-
tor characteristic curve (ROC) analysis to identify the most appropriate cut-off point were clas-
sified as ‘acceptable’ quality. Studies in which administrators of the screening tool and
diagnostic interview were not blinded to each other’s results, or for which we were unable to
ascertain whether this was the case, were recorded as unblinded.
Data Extraction
Data extraction forms were piloted and finalised in March 2014. Data were extracted on disor-
ders, screening tools, gold standards, tool administrators, study settings, study populations,
sample sizes and psychometric properties of the screening tools. The key measures of screening
tool performance were area under the receiver operating characteristic curve (AUC), sensitivity
and specificity. Where available, data were also extracted on predictive values, correct classifi-
cation rate, internal consistency (Cronbach’s alpha coefficient) and test-retest reliability.
Where data were not reported in the published paper, authors were contacted by email. Infor-
mation obtained in this manner was added to the data table available as a web appendix (S1
File), on figshare and on MHIN.
Data Analysis
For each validation, the diagnostic odds ratio (DOR) [25] was calculated using the following
formula:
DOR ¼ Sensitivity=ð100 SensitivityÞð100 SpecificityÞ=Specificity
DOR is a measure of screening tool effectiveness. It is defined as the ratio of the odds of a
true positive screening positive relative to the odds of a true negative screening positive. Possi-
ble results range from 0 to infinity, with higher ratios indicating a better performing test. DOR
increases very steeply as sensitivity and specificity tend towards 100%, so the following cut-offs
were applied to rate screening tool validity: DOR50 for very strong validity, 50>DOR20 for
strong, 20>DOR10 for fair and 10>DOR for weak. Although the same DOR can correspond
to different combinations of sensitivity and specificity, it provides an acceptable comparison of
the tools included in this review, because for each validation we have reported psychometric
properties of the tool at the cut-off point that best balances sensitivity and specificity, as deter-
mined by the ROC analysis [25].
Table 1. Quality Criteria.
1 Was expectation bias avoided?
(Were people administering the diagnostic interview blind to the results of the screening tool, and vice
versa?)
2 Was work-up bias avoided?
(Did positive and negative screens have an equal chance of receiving the full diagnostic interview?)
3 Was a sensible ‘normal range’ derived from the results?
(Was ROC analysis used to identify the most appropriate cut-off point?)
4 Was the tool appropriately translated, adapted and/or designed for the study setting and population?
(If using an existing tool, did authors employ the standardized WHO translation protocol? [24])
5 Were conﬁdence intervals given for AUC, sensitivity, speciﬁcity and other psychometric features of the
test?
6 Was the tool shown to be reproducible both within and/or between observers?
(Was test-retest and/or inter-rater reliability assessed?)
doi:10.1371/journal.pone.0156939.t001
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Average DOR results weighted by sample size were calculated for each screening tool to
compare their effectiveness. Where a study reported significantly higher DOR than the norm, a
second weighted average was calculated to exclude the outlier and produce a more reliable esti-
mate of the screening tool’s validity in most LMIC settings and populations.
Results
Study Selection
The initial database search returned 5,443 original hits, from which 277 studies were identified
as potentially relevant from their titles and abstracts. 274 full-text papers were retrieved and
130 of these met the criteria for inclusion. The reference lists of these 130 papers were then
scanned for additional relevant studies not identified by the initial search. This, along with
assessment of four existing systematic reviews [18–21], provided an additional 23 studies for
inclusion. The total number of included studies was therefore 153. Fig 2 provides a flow dia-
gram of this process, and a full list of included studies with references is available as a web
appendix (S2 File) and on MHIN.
Quality Appraisal
12 studies met all six quality criteria and were therefore classified as ‘very good’ quality. 88
studies were of ‘good’ quality, with the most commonly missed criteria being failure to report
confidence intervals (criteria 5) and no attempt to assess the tool’s reproducibility (criteria 6).
25 studies were classed as ‘fair’ quality; 12 because they failed to avoid work-up bias and a fur-
ther 13 because they met this criteria but did not meet criteria 4, 5 or 6.
11 studies were considered to be of ‘acceptable’ quality due to failure to conduct a ROC anal-
ysis to identify the tool’s optimum cut-off point for the population of interest. 17 studies were
recorded as ‘unblinded’ (4 confirmed that the tool administrators were not blinded; 13 did not
report on blinding and did not respond when contacted). A detailed breakdown of this quality
appraisal is available as an online appendix (S3 File) and on MHIN.
Description of Included Studies
Because several studies validate multiple tools, the 153 included studies correspond to 273
screening tool validations. Of these, 61 validate tools for any CMD, 175 for depressive disor-
ders, 24 for anxiety disorders, and 13 for PTSD. Table 2 presents the CMDs for which screen-
ing tool validation studies were identified for this review.
Fig 2. Study selection flow diagram.
doi:10.1371/journal.pone.0156939.g002
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Table 3 describes the populations sampled in the included studies. Perinatal women and
people attending primary care clinics were particularly well-represented groups, while children
and adolescents were under-represented. Of the 153 included studies, only 17 (11%) validated
screenings tools to identify CMDs in children or adolescents, though in LMIC the proportion
of the total population under age 15 ranges from 20 to 50%.
Of the 153 studies eligible for inclusion in this review: 66 were conducted in Asia, 46 in
South and Central America, 40 in Africa, and just 3 in East and Central Europe. This implies a
geographically uneven distribution of research into CMD screening tool validity in LMIC,
which becomes far more pronounced when looking within continents. For example, of the 43
South American studies meeting the inclusion criteria, over three quarters (33) were conducted
in Brazil. Table 4 highlights this and other disparities in the geographic distribution of existing
evidence, including the number of countries in each region for which no study was identified.
Table 2. Disorders for which screening tools were validated by studies included in this review.
Common Mental Disorders Any common mental disorder
(61 validations)
Dysthemia
Any depressive disorder
Depressive Disorders Major depressive disorder
(175 validations) Antenatal depression
Postnatal depression
Postnatal major depressive disorder
Any anxiety disorder
Anxiety Disorders Generalised anxiety disorder
(24 validations) Social anxiety disorder
Panic disorder
Post-traumatic stress disorder Post-traumatic stress disorder
(13 validations)
doi:10.1371/journal.pone.0156939.t002
Table 3. Number of validation studies for each population group.
Population Number of Studies
Child & Adolescent 17
Perinatal Antenatal 9
Postnatal 27
Clinic attendees 34
HIV+ 6
Physically ill 9
Adult Mentally ill 8
Trauma survivors 5
General population 20
University students 8
Elderly 15
158
Total (5 of the 153 studies sampled from populations
representing two of the above groups)
doi:10.1371/journal.pone.0156939.t003
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Summary of Screening Tool Validity
Although it would be inappropriate to recommend ‘best’ screening tools for use in LMIC, we
can make broad statements about the tools’ psychometric properties and their overall relative
performance. Table 5 presents the weighted diagnostic odds ratio (DOR) of screening tools for
which more than one study examined the tool’s ability to screen for a particular diagnosis.
Table 5 categorises the validity of these screening tools according to their diagnostic odds ratio:
DOR50 for very strong validity, 50>DOR20 for strong, 20>DOR10 for fair and
10>DOR for weak.
Although not shown in Table 5, as they were only validated in one study each, many of the
best performing tools included in this review are those developed from scratch for specific pop-
ulations in particular settings. This process of tool development consists of either interviews
with patients or analysis of psychiatric case notes to identify common idioms and symptom
expression of CMDs in the local context. The following tools all performed with DORs of well
Table 4. Number of validation studies by subregion and country.
Region (# studies) Countries Included (# studies)
Central (1) Cameroon (1)
7 LMIC countries with 0 studies
East (19) Burundi (2), Ethiopia (3), Malawi (1), Rwanda (1), Somalia (1), Uganda (4),
Zambia (4), Zimbabwe (3)
11 LMIC countries with 0 studies
Africa North (3) Egypt (2), Morocco (1)
(40) 5 LMIC countries with 0 studies
South (8) Botswana (1), South Africa (7)
3 LMIC countries with 0 studies
West (9) Burkina Faso (1), Nigeria (8)
15 LMIC countries with 0 studies
Caribbean (0) 17 LMIC countries with 0 studies
America Central (3) Honduras (1), Mexico (2)
(46) 6 LMIC countries with 0 studies
South (43) Brazil (33), Chile (1), Colombia (8), Peru (1)
7 LMIC countries with 0 studies
Central (1) Tajikistan (1)
4 LMIC country with 0 studies
East (16) China (15), Mongolia (1)
1 LMIC country with 0 studies
Asia South (23) Bangladesh (1), India (12), Iran(4), Nepal (2), Pakistan (1), Sri Lanka (3)
(66) 3 LMIC countries with 0 studies
Southeast
(18)
Malaysia (7), Thailand (7), Vietnam (4)
6 LMIC countries with 0 studies
West (8) Lebanon (3), Turkey (5)
8 LMIC countries with 0 studies
Europe East (0) 6 LMIC countries with 0 studies
(1) South(1) Bosnia & Herzegovina (1)
5 LMIC countries with 0 studies
Oceania (0) 16 LMIC countries with 0 studies
Total (153) 102 LMIC countries with 0 studies
doi:10.1371/journal.pone.0156939.t004
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over 100: case description for CMDs in China [26], the Chinese Military Mental Health Scale
(CMMHS) for CMDs [27], and the Pakistan Anxiety and Depression Questionnaire (PADQ)
[28]. The first two of these results come from good quality studies, though the third is of
acceptable quality. A full table of results, including diagnostic odds ratios for all screening tool
validations, is available as a web appendix (S1 File), on figshare and on MHIN.
Discussion
Choosing a Screening Tool
Although this review provides a comprehensive summary of the existing literature, and can
therefore recommend screening tools that are likely to perform well in a given setting, local val-
idation should still be conducted wherever possible. Where the resources exist to do so, a pilot
study should always be carried out to validate the chosen screening tool against a gold standard
diagnostic interview, confirming its validity for the study population.
Many of the best performing tools included in this review are those that were locally
adapted. Where possible, a screening tool’s validity should therefore always be improved
through local adaptation. Focus group discussions with representatives of the population in
which the screening tool is to be implemented should be conducted, with two key aims. The
first is to ensure that all questions are correctly understood and that none cause any discomfort
to either interviewers or respondents. The second is to better understand local experience and
Table 5. Weighted diagnostics odds ratios (DORs) of selected screening tools.
Screening Tool Disorder Number of Studies Weighted DOR (excluding outliers)
*GHQ-5* *CMD* *2* *59.82*
SRQ-20 CMD 14 28.36
GHQ-12 CMD 13 22.59
K-6 CMD 2 15.61
K-10 CMD 2 15.55
GHQ-28 CMD 2 15.31
SSQ CMD 2 9.37
EPDS CMD 3 7.01
HADS-D Depressive disorders 8 33.07
PHQ-9 Depressive disorders 5 27.52
PHQ-2 Depressive disorders 2 22.18
BDI Depressive disorders 2 16.14
EPDS Depressive disorders 3 4.95
ZSDS Major depressive disorder 4 36.47
GDS-15 Major depressive disorder 4 31.97
HADS-D Major depressive disorder 3 22.77
PHQ-9 Major depressive disorder 11 19.22
CES-D Major depressive disorder 6 18.79
BDI Major depressive disorder 4 15.18
K-10 Major depressive disorder 3 8.58
*EPDS* *Postnatal major depressive disorder* *4* *172.70*
*EPDS* *Postnatal depression* *13* *148.68*
EPDS Antenatal depression 4 16.14
*HADS-A* *Anxiety disorders* *8* *60.09*
Screening tool validity = *Very strong*, strong, fair, weak
doi:10.1371/journal.pone.0156939.t005
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expression of mental illness, allowing for local idioms of distress to be incorporated into the
questionnaire.
Screening Tools for any CMD. We identified validation studies for 25 different tools
screening for any CMD (including variants on the same baseline tool in terms of language or
number of items). Of these, the GHQ-5/12 and SRQ-20 demonstrate the strongest psychomet-
ric properties. The SRQ-20’s binomial response format makes it particularly valuable for CMD
screening in LMIC, as it can be effectively administered by lay interviewers with only minimal
training, as well as easily understood and completed by respondents with low literacy [29]. The
GHQ-12 andHADS are particularly appropriate for detecting psychiatric morbidity in physi-
cally ill patients because, unlike the GHQ-30, they do not include questions about somatic
symptoms [30].
Screening Tools for Depressive Disorders. Validation studies were found for 63 different
tools screening for depressive disorders. The PHQ-9 is one of the most commonly used depres-
sion screening tools, perhaps because it was the first to efficiently establish psychiatric diagno-
ses based on DSM-IV criteria. This review’s findings, however, do not strongly support its use
in low resource LMIC settings. The PHQ-9 performs very well in two large studies conducted
in university student populations [31, 32], but poorly in several clinic populations with lower
average education [33–35]. We therefore recommend the PHQ-9 to screen for depressive dis-
orders in high literacy population groups, but suggest that it may not be an appropriate tool for
people with low literacy. After excluding outlying results, we found that the average perfor-
mance of the HADS-D was slightly better than that of the PHQ-9, therefore also recommend
theHADS-D for consideration when selecting a screening tool for depression.
The EPDS consistently performs very well as a screen for postnatal depression. Two quali-
ties that make it particularly suitable for use in LMIC are its brevity and avoidance of the word
‘depression’ [36]. Comprising just ten items, the EPDS is relatively quick to complete and can
be easily incorporated into existing postnatal services. We therefore strongly recommend the
EPDS to screen for depression in postnatal women, but it performs much less well in other
populations.
Screening Tools for Anxiety Disorders. This review finds that 11 different anxiety disor-
der screening tools have been validated for use in LMIC. Of these, theHADS-A performs nota-
bly better than the others. TheHADS is unusual in its ability to detect specific mood states,
and we particularly recommend its anxiety subscale (HADS-A) as a screen for anxiety
disorders.
Screening Tools for PTSD. The evidence on screening tool validity for PTSD in LMIC is
very scarce. This is particularly concerning given the research and clinical interest in the trau-
matic effects of humanitarian crises. Studying these issues requires measurement methods that
have been appropriately validated for these intensely vulnerable populations. We identified
validity studies for ten PTSD screening tools in LMIC. In the absence of sufficient evidence, we
only provisionally recommend continued use of what is currently the most widely validated
tool in LMIC, the HTQ (separate validation studies have been conducted in South Africa, Bos-
nia and Herzegovina, and Tajikistan).
Strengths and Limitations of this Review
This study employed robust methods, such as 10% double screening at every stage of the
search, and the use of standardised quality assessment criteria. Five databases were systemati-
cally searched and all potentially relevant papers were read in full. The decision to work with
relatively limited exclusion criteria has maximised the scope of the evidence covered here for
reference by researchers, policy makers and health workers.
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On the other hand, inclusion was restricted to studies that validated the screening tool
against a gold standard diagnostic interview. As with the brief screening tools we are interested
in validating, these gold standards were developed for use in high income country populations.
It is important to consider whether it is appropriate to treat them as a true gold standard for
diagnosing CMDs in LMIC, and the extent to which this might limit our findings.
The validity of the conclusions drawn from this review is limited by the quality of the
included studies. We were not able to calculate confidence intervals for weighted diagnostic
odds ratios as very few of the included studies reported confidence intervals for sensitivity and
specificity. That some studies failed to guard against expectation or work-up bias is also cause
for concern. Although sample size was integrated into the average DOR calculations, overall
quality scores were not taken into account, which we recognise as a limitation. We were also
unable to conduct sensitivity analyses to explore the effect of study quality, due to the low num-
ber of studies for each tool and the large amount of between-study heterogeneity. Instead, full
details of each study’s quality are provided as an online appendix (S3 File) and on MHIN,
allowing readers to consider the quality of the individual studies conducted in the contexts that
best reflect their own. As well as the risk of bias within studies, there is a risk of publication bias
across studies due to the tendency to over-report positive findings, though this bias is likely to
be the same for all screening tools and therefore should have little effect on relative validity.
Several additional studies were identified through a hand search, suggesting a limitation in the
search strategy. Although this was developed in consultation with a qualified librarian, it may be
necessary for future reviews to adapt the search terms in order to improve sensitivity. Possible
issues to keep in mind include the varied terminology used to describe commonmental disorders.
Recommendations for Future Research
It is difficult to draw reliable conclusions from such a heterogeneous set of studies. In order to
facilitate future reviews comparing screening tool validity, a set of methodological standards
should be agreed upon for validation studies. We suggest that the screening tool should be con-
ducted by a lay interviewer or general health worker, and the gold standard diagnostic interview
by a mental health professional. In order to address concerns about the validity of so-called ‘gold
standards’, we also recommend the validation of diagnostic interviews in LMIC populations.
This review employed broad inclusion criteria and relaxed quality criteria, thus identifying
153 studies for inclusion. Despite the large total number of studies, there are significant biases
in the existing evidence. While there is plentiful evidence for screening tool validity for particu-
lar disorders in particular settings–for example depression in Brazil–huge gaps remain. There
are over 100 LMIC for which no CMD screening tool validation study was identified for inclu-
sion in this review. Further research is required to test the validity of screening tools in most
LMIC settings and populations, particularly in those countries for which no validation studies
have been conducted. There is a particular shortage of studies validating tools for use in com-
munity populations [31], and this review highlights a lack of attention to child and adolescent
mental health. Screening tools for depression have been much more widely validated than
those for anxiety and PTSD, or even for common mental disorders more broadly. These gaps
should be made priorities for future research. We also recommend a shift in focus away from
screening tools for narrowly defined disorders, and encourage the development of better trans-
diagnostic screens.
Conclusions
Our results reinforce the importance of validating brief CMD screening tools for the particular
populations and settings in which they are being applied. They demonstrate that a screening
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tool’s ability to accurately detect CMDs can vary significantly depending on the population in
which it is administered, as can the most appropriate cut-off point for positive/negative classifi-
cation. Our primary recommendation is that, wherever possible, a chosen screening tool
should be validated against a gold standard diagnostic assessment in the specific context.
Where this is not possible, health care professionals, researchers and policymakers can refer to
the database of validation studies provided in the web appendix (S1 File), on figshare and on
MHIN, to identify previous studies conducted in the region, country, population group and
research setting of interest.
Many of the best performing tools were developed or adapted for specific populations; how-
ever, as these tools were only validated in one study, it is not possible to draw broader conclu-
sions about their applicability in other contexts. Of the tools that have been validated in
multiple settings, the authors broadly recommend using the SRQ-20 to screen for general
CMDs, the GHQ-12 for CMDs in people with physical illness, the HADS-D for depressive dis-
orders, the PHQ-9 for depressive disorders in populations with good literacy levels, the EPDS
for perinatal depressive disorders, and the HADS-A for anxiety disorders.
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